The French National Cancer Institute established a national network in 2006, providing a routine panel of biomarkers, including EGFR, KRAS, BRAF, PI3KCA and HER2 mutations and ALK rearrangements in patients with advanced NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.